• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Sell­ing shares at a dis­count, Zymeworks grabs $100M cash in hopes of turn­around

4 years ago
Financing

Un­der pres­sure, Bio­gen out­lines am­bi­tious di­ver­si­ty goals for Aduhelm study — but the Medicare fight is still on

4 years ago
Pharma
FDA+

Pfiz­er wants to help the FDA with its new, court-man­dat­ed $4-5M FOIA re­lease on the com­pa­ny's Covid-19 vac­cine da­ta

4 years ago
FDA+
Coronavirus

A new Third Rock start­up seeks a 'sec­ond gold­en age' of GPCR drug dis­cov­ery based on No­bel lau­re­ate's work

4 years ago
Financing
Startups

Big Phar­ma R&D leg­end Paul Stof­fels is trad­ing his J&J ti­tle for the CEO role at one of the most deeply trou­bled ...

4 years ago
People

Af­ter a ban­ner year, Sam­sung will charge for­ward with 'su­per plan­t' plans, and look to ex­pand abroad

4 years ago
Pharma
Manufacturing

As Omi­cron-spe­cif­ic boost­ers are in the news, BioN­Tech to ex­pand Ger­man site work­force by 200 em­ploy­ees

4 years ago
Manufacturing

Roche nabs a pri­or­i­ty re­view for Evrys­di, hop­ing to be­come the first oral treat­ment for in­fants with SMA

4 years ago
Pharma
FDA+

A se­nior Bio­gen com­mer­cial ex­ec ex­its Alzheimer's unit amid ex­o­dus as Aduhelm woes mount

4 years ago
Pharma

No­var­tis mar­ket­ing vets move on to new com­mer­cial roles in biotech

4 years ago
People
Pharma

As Sanofi keeps shrink­ing its US HQ foot­print dur­ing pan­dem­ic, new own­ers scoop up its old cam­pus

4 years ago
Pharma

Celebri­ty cou­ple ac­tress Gabrielle Union and re­tired NBA star Dwyane Wade reprise roles in Mer­ck vac­ci­na­tion cam­paign

4 years ago
Pharma
Marketing

FDA+ roundup: Janet Wood­cock de­fends her 'most' will get Covid com­ment, talks short­ages and gov­ern­ment trust

4 years ago
FDA+

Biotech bears are maul­ing stocks as 2022 opens on a bleak note for in­vestors

4 years ago
Financing
Deals

Cor­texyme switch­es di­rec­tion, an­nounces lay­offs af­ter FDA slaps hold on dark horse Alzheimer’s can­di­date

4 years ago
FDA+

Cy­to­Dyn fires em­bat­tled CEO as its grow­ing cho­rus of crit­ics gets loud­er

4 years ago
People

Mi­cro­cap can­cer play­er goes bel­ly up af­ter pan­cre­at­ic tu­mor hope­ful flops key study

4 years ago
R&D

Dig­i­tal med com­pa­ny Ak­ili set to go pub­lic via Pal­i­hapi­tiya-backed SPAC — fur­ther­ing com­mer­cial launch and pipeline ...

4 years ago
Financing
R&D

Sanofi claims high-ris­es neigh­bor­ing its Toron­to fa­cil­i­ty would pose 'na­tion­al se­cu­ri­ty' threat

4 years ago
Pharma

FDA hur­ries up a quick ap­proval for the world's first TCR — af­ter a 14-year R&D trek

4 years ago
FDA+

Well-con­nect­ed, Gilead-backed biotech gets an­oth­er stack of cash to pur­sue CAR-Ts for au­toim­mune dis­ease

4 years ago
Financing
Cell/Gene Tx

Days af­ter Gilead yanks PI3K drug, In­cyte with­draws NDA for its own PI3K — say­ing con­fir­ma­to­ry tri­als would take ...

4 years ago
FDA+

In a set­back, FDA or­ders Gilead to hit the brakes on their late-stage, $5B can­cer play

4 years ago
R&D
FDA+

Opin­ion: Flori­da is so mAb crazy, Ron De­San­tis wants to use mAbs that don't work

4 years ago
R&D
First page Previous page 593594595596597598599 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times